Monopar Therapeutics (MNPR) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16
	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenues	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross margin	0.0%
Selling, general and administrative [+]	2.9	2.6	2.4	2.4	1.6	1.2	0.9
General and administrative	2.9	2.6	2.4	2.4	1.6	1.2	0.9
Research and development	7.6	6.5	4.1	2.0	1.8	0.9	0.3
EBIT [+]	-10.5	-9.1	-6.5	-4.3	-3.3	-2.1	-1.2
EBIT growth	15.4%	40.2%	50.5%	29.8%	58.5%	76.2%
EBIT margin	-12659.3%
Non-recurring items [+]						14.5
In-process research & development						14.5
Interest income	0.0	0.0	0.1	0.1	0.1	0.0	0.0
Interest income	0.0	0.0	0.1	0.1	0.1	0.0	0.0
Other income (expense), net [+]			0.1				0.0
Other			0.1
Pre-tax income	-10.5	-9.1	-6.3	-4.2	-3.2	-16.6	-1.2
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%		0.0%	0.0%	0.0%
Net income	-10.5	-9.1	-6.3	-4.2	-3.2	-16.6	-1.2
Net margin	-12633.8%

Basic EPS [+]	($0.83)	($0.73)	($0.58)	($0.45)	($0.35)	($1.89)
Growth	13.3%	26.9%	26.9%	30.5%	-81.6%
Diluted EPS [+]	($0.83)	($0.73)	($0.58)	($0.45)	($0.35)	($1.89)
Growth	13.3%	26.9%	26.9%	30.5%	-81.6%

Shares outstanding (basic) [+]	12.7	12.5	11.0	9.3	9.3	8.8
Growth	2.0%	13.8%	17.6%	0.3%	5.8%
Shares outstanding (diluted) [+]	12.7	12.5	11.0	9.3	9.3	8.8
Growth	2.0%	13.8%	17.6%	0.3%	5.8%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.